Calmodulin kinase II inhibition disrupts cardiomyopathic effects of enhanced green fluorescent protein

Michelle S C Khoo; Chad E. Grueter; Mesut Eren; Jinying Yang; Rong Zhang; Martha A. Bass; Seint T. Lwin; Lisa A. Mendes; Douglas E. Vaughan; Roger J. Colbran; Mark E. Anderson

doi:10.1016/j.yjmcc.2007.10.014

Calmodulin kinase II inhibition disrupts cardiomyopathic effects of enhanced green fluorescent protein

Michelle S C Khoo, Chad E. Grueter, Mesut Eren, Jinying Yang, Rong Zhang, Martha A. Bass, Seint T. Lwin, Lisa A. Mendes, Douglas E. Vaughan, Roger J. Colbran, Mark E. Anderson^*

^*Corresponding author for this work

Medicine, Cardiology Division

Research output: Contribution to journal › Article › peer-review

3 Scopus citations

Abstract

Transgenic expression of enhanced green fluorescent protein (eGFP) in myocardium can result in cardiac dysfunction and cardiomyopathy, presumably through toxic effects that disrupt normal cellular signaling. The multifunctional Ca²⁺- and calmodulin-dependent protein kinase II (CaMKII) is widely expressed in myocardium and CaMKII activity is increased in human and animal models of cardiomyopathy, so we hypothesized that increased CaMKII activity is important for cardiomyopathy due to transgenic expression of eGFP. Here we report that cardiomyocyte-delimited eGFP over-expression causes increased CaMKII activity that predicts left ventricular dilation and dysfunction. On the other hand, transgenic co-expression of a CaMKII inhibitory peptide with eGFP prevents eGFP-mediated left ventricular dilation and dysfunction. These findings suggest that increased CaMKII activity is a critical pathological signal in transgenic cardiomyopathy due to eGFP over-expression.

Original language	English (US)
Pages (from-to)	405-410
Number of pages	6
Journal	Journal of Molecular and Cellular Cardiology
Volume	44
Issue number	2
DOIs	https://doi.org/10.1016/j.yjmcc.2007.10.014
State	Published - Feb 2008

Keywords

Calmodulin kinase II
Cardiomyopathy
eGFP

ASJC Scopus subject areas

Molecular Biology
Cardiology and Cardiovascular Medicine

Access to Document

10.1016/j.yjmcc.2007.10.014

Fingerprint Dive into the research topics of 'Calmodulin kinase II inhibition disrupts cardiomyopathic effects of enhanced green fluorescent protein'. Together they form a unique fingerprint.

Cite this

Khoo, M. S. C., Grueter, C. E., Eren, M., Yang, J., Zhang, R., Bass, M. A., Lwin, S. T., Mendes, L. A., Vaughan, D. E., Colbran, R. J., & Anderson, M. E. (2008). Calmodulin kinase II inhibition disrupts cardiomyopathic effects of enhanced green fluorescent protein. Journal of Molecular and Cellular Cardiology, 44(2), 405-410. https://doi.org/10.1016/j.yjmcc.2007.10.014

Khoo, Michelle S C ; Grueter, Chad E. ; Eren, Mesut ; Yang, Jinying ; Zhang, Rong ; Bass, Martha A. ; Lwin, Seint T. ; Mendes, Lisa A. ; Vaughan, Douglas E. ; Colbran, Roger J. ; Anderson, Mark E. / Calmodulin kinase II inhibition disrupts cardiomyopathic effects of enhanced green fluorescent protein. In: Journal of Molecular and Cellular Cardiology. 2008 ; Vol. 44, No. 2. pp. 405-410.

@article{9ac0fa38c2574421bc0bc6e879174b57,

title = "Calmodulin kinase II inhibition disrupts cardiomyopathic effects of enhanced green fluorescent protein",

abstract = "Transgenic expression of enhanced green fluorescent protein (eGFP) in myocardium can result in cardiac dysfunction and cardiomyopathy, presumably through toxic effects that disrupt normal cellular signaling. The multifunctional Ca2+- and calmodulin-dependent protein kinase II (CaMKII) is widely expressed in myocardium and CaMKII activity is increased in human and animal models of cardiomyopathy, so we hypothesized that increased CaMKII activity is important for cardiomyopathy due to transgenic expression of eGFP. Here we report that cardiomyocyte-delimited eGFP over-expression causes increased CaMKII activity that predicts left ventricular dilation and dysfunction. On the other hand, transgenic co-expression of a CaMKII inhibitory peptide with eGFP prevents eGFP-mediated left ventricular dilation and dysfunction. These findings suggest that increased CaMKII activity is a critical pathological signal in transgenic cardiomyopathy due to eGFP over-expression.",

keywords = "Calmodulin kinase II, Cardiomyopathy, eGFP",

author = "Khoo, {Michelle S C} and Grueter, {Chad E.} and Mesut Eren and Jinying Yang and Rong Zhang and Bass, {Martha A.} and Lwin, {Seint T.} and Mendes, {Lisa A.} and Vaughan, {Douglas E.} and Colbran, {Roger J.} and Anderson, {Mark E.}",

note = "Funding Information: This work was funded by NIH R01 HL 079031, R01 HL 62494, and R01 HL 70250 and the University of Iowa Research Foundation. Dr Khoo was funded by grant 9920117V from the American Heart Association (SE Affiliate). Copyright: Copyright 2008 Elsevier B.V., All rights reserved.",

year = "2008",

month = feb,

doi = "10.1016/j.yjmcc.2007.10.014",

language = "English (US)",

volume = "44",

pages = "405--410",

journal = "Journal of Molecular and Cellular Cardiology",

issn = "0022-2828",

publisher = "Academic Press Inc.",

number = "2",

}

Calmodulin kinase II inhibition disrupts cardiomyopathic effects of enhanced green fluorescent protein. / Khoo, Michelle S C; Grueter, Chad E.; Eren, Mesut; Yang, Jinying; Zhang, Rong; Bass, Martha A.; Lwin, Seint T.; Mendes, Lisa A.; Vaughan, Douglas E.; Colbran, Roger J.; Anderson, Mark E.

In: Journal of Molecular and Cellular Cardiology, Vol. 44, No. 2, 02.2008, p. 405-410.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - Calmodulin kinase II inhibition disrupts cardiomyopathic effects of enhanced green fluorescent protein

AU - Khoo, Michelle S C

AU - Grueter, Chad E.

AU - Eren, Mesut

AU - Yang, Jinying

AU - Zhang, Rong

AU - Bass, Martha A.

AU - Lwin, Seint T.

AU - Mendes, Lisa A.

AU - Vaughan, Douglas E.

AU - Colbran, Roger J.

AU - Anderson, Mark E.

N1 - Funding Information: This work was funded by NIH R01 HL 079031, R01 HL 62494, and R01 HL 70250 and the University of Iowa Research Foundation. Dr Khoo was funded by grant 9920117V from the American Heart Association (SE Affiliate). Copyright: Copyright 2008 Elsevier B.V., All rights reserved.

PY - 2008/2

Y1 - 2008/2

N2 - Transgenic expression of enhanced green fluorescent protein (eGFP) in myocardium can result in cardiac dysfunction and cardiomyopathy, presumably through toxic effects that disrupt normal cellular signaling. The multifunctional Ca2+- and calmodulin-dependent protein kinase II (CaMKII) is widely expressed in myocardium and CaMKII activity is increased in human and animal models of cardiomyopathy, so we hypothesized that increased CaMKII activity is important for cardiomyopathy due to transgenic expression of eGFP. Here we report that cardiomyocyte-delimited eGFP over-expression causes increased CaMKII activity that predicts left ventricular dilation and dysfunction. On the other hand, transgenic co-expression of a CaMKII inhibitory peptide with eGFP prevents eGFP-mediated left ventricular dilation and dysfunction. These findings suggest that increased CaMKII activity is a critical pathological signal in transgenic cardiomyopathy due to eGFP over-expression.

AB - Transgenic expression of enhanced green fluorescent protein (eGFP) in myocardium can result in cardiac dysfunction and cardiomyopathy, presumably through toxic effects that disrupt normal cellular signaling. The multifunctional Ca2+- and calmodulin-dependent protein kinase II (CaMKII) is widely expressed in myocardium and CaMKII activity is increased in human and animal models of cardiomyopathy, so we hypothesized that increased CaMKII activity is important for cardiomyopathy due to transgenic expression of eGFP. Here we report that cardiomyocyte-delimited eGFP over-expression causes increased CaMKII activity that predicts left ventricular dilation and dysfunction. On the other hand, transgenic co-expression of a CaMKII inhibitory peptide with eGFP prevents eGFP-mediated left ventricular dilation and dysfunction. These findings suggest that increased CaMKII activity is a critical pathological signal in transgenic cardiomyopathy due to eGFP over-expression.

KW - Calmodulin kinase II

KW - Cardiomyopathy

KW - eGFP

UR - http://www.scopus.com/inward/record.url?scp=38949097498&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=38949097498&partnerID=8YFLogxK

U2 - 10.1016/j.yjmcc.2007.10.014

DO - 10.1016/j.yjmcc.2007.10.014

M3 - Article

C2 - 18048055

AN - SCOPUS:38949097498

VL - 44

SP - 405

EP - 410

JO - Journal of Molecular and Cellular Cardiology

JF - Journal of Molecular and Cellular Cardiology

SN - 0022-2828

IS - 2

ER -

Calmodulin kinase II inhibition disrupts cardiomyopathic effects of enhanced green fluorescent protein

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this